AXSOME THERAPEUTICS I
99.65
27-November-24 16:45:00
15 minutes delayed
Stocks
+2.62
+2.70%
Today's range
96.50 - 100.48
ISIN
N/A
Source
NASDAQ
-
Axsome Therapeutics Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting
29 Sep 2022 07:28:00 By Nasdaq GlobeNewswire
-
Axsome Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference
21 Sep 2022 07:00:00 By Nasdaq GlobeNewswire
-
Axsome Therapeutics to Present at the Cowen 2nd Annual Novel Mechanisms in Neuropsychiatry Summit
14 Sep 2022 07:00:01 By Nasdaq GlobeNewswire
-
Axsome Therapeutics Initiates ADVANCE-2 Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation
08 Sep 2022 07:00:01 By Nasdaq GlobeNewswire
-
Axsome Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
06 Sep 2022 07:00:01 By Nasdaq GlobeNewswire
-
01 Sep 2022 07:00:00 By Nasdaq GlobeNewswire
-
19 Aug 2022 06:45:03 By Nasdaq GlobeNewswire
-
Axsome Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
09 Aug 2022 07:00:01 By Nasdaq GlobeNewswire
-
Axsome Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
28 Jul 2022 07:00:02 By Nasdaq GlobeNewswire
-
Axsome Therapeutics Hosts Sunosi® Investor Update Virtual Event Today with Key Opinion Leaders
28 Jun 2022 07:00:00 By Nasdaq GlobeNewswire
-
Axsome Therapeutics to Host Sunosi® Investor Update Virtual Event
22 Jun 2022 07:00:01 By Nasdaq GlobeNewswire
-
02 Jun 2022 07:00:01 By Nasdaq GlobeNewswire
-
31 May 2022 07:39:37 By Nasdaq GlobeNewswire
-
09 May 2022 08:57:19 By Nasdaq GlobeNewswire
-
28 Mar 2022 06:00:00 By Nasdaq GlobeNewswire
-
Axsome Therapeutics to Participate in the 1st Annual Needham Virtual Neuroscience Forum
11 Mar 2022 07:00:00 By Nasdaq GlobeNewswire